

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3 Attorney Docket Number 27373/38819A

## Complete if Known

Application Number	10/530,774
Filing Date	April 7, 2005
First Named Inventor	Bernard Roizman
Art Unit	1648
Examiner Name	Not Yet Assigned

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	Debinski, et al., "Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas," <i>Clin. Cancer Res.</i> 5:985-990 (1999)		
	Debinski, et al., "Retargeting Interleukin 13 for Radioimmuno detection and Radioimmunotherapy of Human High-grade Gliomas," <i>Clin. Cancer Res.</i> 5(10 Suppl):3143s-3147s (1999)		
	Debinski, et al., "Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-Associated Cancer/Testis Antigen," <i>Mol. Med.</i> 6:440-449 (2000)		
	de Vries et al., "Scintigraphic Imaging of HSVtk Gene Therapy," <i>Current Pharmaceutical Design</i> 8:1435-1450 (2002)		
	de Vries, et al., "Positron emission tomography: measurement of transgene expression," <i>Methods</i> 27(3):234-241 (2002)		
	Ellerman, et al., "Identification of a Determinant of Epidermal Growth Factor Receptor Ligand-Binding Specificity Using a Tuncated, High-Affinity Form of the Ectodomain," <i>Biochemistry</i> 40:8930-8939 (2001)		
	Fracasso, et al., "Anti-tumor Effects of Toxins Targeted to the Prostate Specific Membrane Antigen," <i>Prostate</i> 53:9-23 (2002)		
	Gembitsky, et al., "A specific binding site for a fragment of the B-loop of epidermal growth factor and related peptides," <i>Peptides</i> 23:97-102 A. (2001)		
	Hayashi, et al., "MUC1 Mucin Core Protein Binds to the Domain 1 of ICAM-1," <i>Digestion</i> 63:87-92 (2001)		
	He, et al., "Suppression of the Phenotype of $\gamma$ , 34.5' Herpes Simplex Virus 1: Failure of Activated RNA-Dependent Protein Kinase to Shut Off Protein Synthesis is Associated with a Deletion in the Domain of the $\alpha$ 47 Gene," <i>J. Virol.</i> 71(8):6049-54 (1997)		
	International Search Report from PCT/US03/31598 (2004)		
	Laquerre, et al., "Heparan Sulfate Proteoglycan Binding by Herpes Simplex virus Type 1 Glycoproteins B and C, Which Differ in Their Contributions to Virus Attachment, Penetration, and Cell-to-Cell Spread," <i>J. Virol.</i> 72(7):6119-30 (1998)		
	Leib, et al., "Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses <i>In Vivo</i> ," <i>J. Exp. Med.</i> 189:663-672 (1999)		
	Lorimer, et al., "Targeting retroviruses to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe," <i>J. Immunol Methods</i> 237(1-2):147-57 (2000)		
	Mabjeesh, et al., "Gene therapy of prostate cancer: current and future directions," <i>Endo. Related Cancer</i> 9:115-139 (2002)		
	Manoj et al., "Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism," <i>Proc. Natl. Acad. Sci. USA</i> , 101: 12414-12421 (2004)		
	Markert, et al., "Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial," <i>Gene Ther.</i> 7(10):867-74 (2000)		
	McKie, et al., "Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevant for gene and cancer therapy," <i>Neuropathol Appl Neurobiol</i> . 24(5):367-72 (1998)		
	Mineta, et al., "Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas," <i>Nat Med.</i> , 1(9):938-43 (1995)		
	Mintz, A., et al., "IL-13R $\alpha$ 2 is a Glioma-Restricted Receptor for Interleukin-13," <i>Neoplasia</i> 4:388-399 (2002)		
	Montgomery, et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NFG Receptor Family," <i>Cell</i> 87:427-436 (1996)		
	Pyles, et al., "A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain Tumors," <i>Human Gene Ther.</i> 8(5):533-44 (1997)		
	Rampling, et al., "Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma," <i>Gene Ther.</i> 7(10):859-66 (2000)		
Examiner Signature	/Mary Mosher/	Date Considered	02/21/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/